

Kentucky 2017 PDMP Legislation

**Kentucky Cabinet for Health and Family Services
November 30, 2017**

Quarterly KASPER Reviews

- House Bill 333 (KRS 218A.202) requires CHFS to conduct quarterly reviews to identify patterns of improper, inappropriate or illegal controlled substance prescribing or dispensing
 - OIG working with licensure boards to review criteria by quarter


Recent KASPER Changes

- A practitioner or pharmacist may access KASPER data for the mother of an infant they are treating for Neonatal Abstinence Syndrome or suspected pre-natal drug exposure (HB 314, KRS 218A.202)
 - Effective June 29, 2017
- Gabapentin is a Schedule V controlled substance in Kentucky (905 KAR 55:035)
 - Effective July 1, 2017

Gabapentin

Kentucky Gabapentin Dispensing			July 2017		August 2017	
			Prescriptions	Doses	Prescriptions	Doses
All Controlled Substances			923,953	58,737,945	977,637	61,641,207
Gabapentin			134,319	13,341,510	144,147	14,387,727
Percent Gabapentin			14.5%	22.7%	14.7%	23.3%

Gabapentin 3Q 2017



Upcoming KASPER Changes

- Authorized practitioners and pharmacists can access available positive drug toxicity screen results related to a patient's suspected drug overdose treated in an ED as well as **all** controlled substances dispensed out of an ED (HB 314, KRS 218A.202)
 - ED controlled substance reporting effective July 2017
 - Drug toxicity screen results to be available January 2018 through the Governor's Office of Electronic Health Information (Kentucky Health Information Exchange)

Upcoming KASPER Changes

- KASPER will allow authorized users to access data on a patient's drug convictions as provided by the Administrative Office of the Courts (SB 32, KRS 218A.202)
 - June 2018